Imiquimod

• Background :

  Imiquimod activates the toll-like receptor7 /8 to secrete cytokines (primarily interferon-α (IFN-α), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α)). It also has been shown to act as an adoside A1 and A2A receptor antagonist. It is clinically useful in the treatment of superficial basal cell carcinoma.

• Description :

  TLR7/8 Agonist

• Product Name Alternative :

  1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; R837; S26308; TMX-101

• UNSPSC :

  41116105

• Type :

  Agonist

• Source :

  Synthetic

• Field of Research :

  Immunology | Innate Immunity | TLR Signaling | Neuroscience | Neurodegeneration | Alzheimer's Disease | Cell Signaling | Protein Phosphorylation | Serine / Threonine Kinases

• Purity :

  >98% (HPLC) ; NMR: (Conforms)

• Weight :

  0.005

• Format :

  White powder

• Solubility :

  May be dissolved in DMSO (2 mg/ml, warm)

• Molecular Formula :

  C14H16N4

• Molecular Weight :

  240.3

• Precautions :

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations :

  1. Kan Y., et al. (2012) J Virol. 86(19): 10338-10346.

• CAS Number :

  99011-02-6